Myriad Genetics Long Term Debt

Myriad Genetics (MYGN) currently reports a long-term debt of $200M as of June 2026. That compares with $86M in the prior-year period — up 135.7% year over year. Use the charts on this page to explore Myriad Genetics's long-term debt history and peer comparisons.

Myriad Genetics's long-term debt increased from $86M to $200M — a 135.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Myriad Genetics reported $200M in long-term debt as of June 2026. That compares with $86M in the prior-year period — up 135.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Myriad Genetics, and consider following MYGN for alerts when major investors trade the stock.

Myriad Genetics is classified in the Healthcare sector. On long-term debt, it currently shows $200M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MYGN with unrelated industries.